Cartesian Therapeutics is trying to turn cell therapy from an inpatient oncology procedure into a six-week outpatient course for autoimmunity, and the second quarter was the financing and partnership quarter meant to carry that claim through a pivotal myasthenia readout. The company is no longer a discovery story. It is a single-asset registrational bet with indication-expansion options, a new senior credit line, and an at-the-market equity program that kept selling stock even after the credit closed. Management ended mid-year with $149 million of cash after drawing the first $50 million from K2 HealthVentures. The investment debate is whether Descartes-08 can deliver a deep, durable response without chemotherapy preconditioning, and whether today's enterprise value is only paying for that one binary.
The operating print was not the story, and treating the reported profit as earnings quality would be a mistake. Research spending rose as the Phase Three AURORA trial advanced, the operating loss widened to $29 million, and a $49 million non-cash gain on contingent value rights flipped the quarter to net income. Those rights pass Swedish Orphan Biovitrum gout proceeds to legacy holders and do not fund the cell-therapy franchise. Cash still rose because the term loan and the ATM both contributed, which is a more honest read than the income statement. The credit is gated, expensive on an all-in basis, and paired with a conversion feature already near the tape. Dilution and debt now sit on the same balance sheet as the readout.
What the next year resolves is whether AURORA reproduces the controlled mid-stage signal in acetylcholine-receptor-positive myasthenia, and whether myositis, pediatric disease, and an in-vivo WestGene construct remain live options or slide into backlog. A clean responder-rate win would justify the pre-commercial spend now being layered onto the burn. A miss would leave a small company with gated remaining tranches, an ATM that is still open, and a platform that has not yet been paid for. The market is not pricing a commercial launch. It is pricing a probability on one outpatient cell-therapy experiment.